Everolimus eluting bioresorbable vascular scaffolds; can we absorb the risk in complex PCI?

Firas Zahr; Joaquin E Cigarroa

doi:10.1002/ccd.27165

Everolimus eluting bioresorbable vascular scaffolds; can we absorb the risk in complex PCI?

Catheter Cardiovasc Interv. 2017 Jul;90(1):70-71. doi: 10.1002/ccd.27165.

Authors

Firas Zahr¹, Joaquin E Cigarroa¹

Affiliation

¹ Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon.

PMID: 28707440
DOI: 10.1002/ccd.27165

Abstract

BVS, as compared with DES, have higher stent thrombosis (ST) rates. BVS may prove reasonable in patients with complex anatomy. Future trials will be necessary to guide clinicians regarding whether BVS are equivalent to DES in patients with noncomplex or complex coronary anatomy.

Publication types

Editorial
Comment

MeSH terms

Absorbable Implants
Coronary Artery Disease*
Drug-Eluting Stents*
Everolimus
Humans
Percutaneous Coronary Intervention*
Time Factors
Treatment Outcome

Substances

Everolimus